RMC-7977

Overview

RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (K d = 195 nM) and KRAS (G12V) (K d = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK , CRAF , and RSK , as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS G12C cancer models, and demonstrates good tolerability across various RAS cancer models.

Application

Products | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > ERK | Products > Signaling Pathways > Raf | Products > Signaling Pathways > Ribosomal S6 Kinase (RSK) | Products > Signaling Pathways > AMPK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PARP | Products > Signaling Pathways > Ras

Product Information

• Catalog No.: HY-156498
• CAS No.: 2765082-12-8
• Molecular Formula: C47H60N8O6S
• Molecular Weight: 865.11
• Purity: 99.48%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2 mg/mL (2.31 mM); Clear solution
• Availability: In-stock

Source

Original product source